| Date Created | Name | Case Status | Approved Date | |
|---|---|---|---|---|
| 8 September 2026 | Susan Bryce | Email hidden; Javascript is required. | Consultation Complete | 10/09/2026 |
| Date Created | Name | Case Status | Approved Date |
| Date Created | Name | Date of Birth | Current Weight | Current Weight (KG) | Current Height (CM) | BMI | Height Feet | Inches | Weight Stones | Pounds | Your BMI | Follow-Up Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 October 2026 | Susie Bryce | 28/05/1983 | 5 | 3 | 10 | 12 | 26.924206027802 | New | ||||
| Date Created | Name | Date of Birth | Current Weight | Current Weight (KG) | Current Height (CM) | BMI | Height Feet | Inches | Weight Stones | Pounds | Your BMI | Follow-Up Status |
| Date of Prescription | Prescription ID | Name | Prescriber Name | Items | Status | |
|---|---|---|---|---|---|---|
| 15/09/2026 | Rx00091 | Susan Bryce | Anna Fenech | Wegovy 0.25mg pre-filled pen - inject once weekly as directed
| Dispensed |
➡️ Print Dispense Label
➡️ Print Prescritpion ➡️ Print Bag Label |
| 16/10/2026 | Rx00117 | Susan Bryce | Anna Fenech | Wegovy 0.5mg pre-filled pen - inject once weekly as directed
| Dispensed |
➡️ Print Dispense Label
➡️ Print Prescritpion ➡️ Print Bag Label |
| Date of Prescription | Prescription ID | Name | Prescriber Name | Items | Status |
client completed follow up questionnaires, no changes in medical history, feels like weight loss slow down and require dose increase, prescription for Wegovy 0.5mg issued
left message
first injection administered correctly, suffered nausea for two days a day after the injection, no other side effects, advice given how to manage, appetite reduced,
Medical history and current medication reviewed. Client reports occasional migraine, managed with naproxen and rizatriptan as required. Currently taking the oral contraceptive pill. BMI 28 kg/m² and waist circumference 90 cm. Assessment consistent with overweight with central adiposity. Client's weight-loss goal is 9 kg.
Discussed treatment with Wegovy (semaglutide) and mechanism of action, including appetite regulation and increased satiety. Benefits, risks and potential adverse effects discussed, including nausea, vomiting, diarrhoea, constipation, abdominal pain and reduced appetite. Advised regarding dietary measures, smaller portion sizes and adequate fluid intake.
Contraception reviewed and advice provided regarding continued effective contraception. Advised that vomiting or severe diarrhoea may affect absorption of the oral contraceptive pill and to follow contraceptive guidance regarding additional precautions if required.
Following discussion, client wishes to proceed with treatment. Wegovy 0.25 mg subcutaneously once weekly commenced as prescribed. Advised to continue dietary and lifestyle measures. Weight, waist circumference, treatment response and tolerability to be monitored, with review prior to dose escalation. Weight-loss target is 9 kg.
| Dispensed Date | Name | Rx Summary | Actions | Print Pack |
|---|---|---|---|---|
| 16/09/2026 | Susan Bryce |
Item 1: Wegovy 0.25mg pre-filled pen Qty: 1 Directions: inject once weekly as directed |
Prescription
Dispense Label Bag Label | |
| 21/10/2026 | Susan Bryce |
Item 1: Wegovy 0.5mg pre-filled pen Qty: 1 Directions: inject once weekly as directed |
Prescription
Dispense Label Bag Label | |
| Dispensed Date | Name | Rx Summary | Actions | Print Pack |
| Order | Date | Status | Total |
|---|---|---|---|
| #2218 | 16/10/2026 | Completed | £131.24 |
| #2151 | 15/09/2026 | Completed | £96.24 |